Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.

Abstract

PURPOSE:

Prophylactic irradiation to the chest wall after diagnostic or therapeutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practice across Europe, although the efficacy of this treatment is uncertain. In this study, we aimed to determine the efficacy of prophylactic radiotherapy in reducing the incidence of chest wall metastases (CWM) after a procedure in MPM.

METHODS:

After undergoing a chest wall procedure, patients with MPM were randomly assigned to receive prophylactic radiotherapy (within 42 days of the procedure) or no radiotherapy. Open thoracotomies, needle biopsies, and indwelling pleural catheters were excluded. Prophylactic radiotherapy was delivered at a dose of 21 Gy in three fractions over three consecutive working days, using a single electron field adapted to maximize coverage of the tract from skin surface to pleura. The primary outcome was the incidence of CWM within 6 months from random assignment, assessed in the intention-to-treat population. Stratification factors included epithelioid histology and intention to give chemotherapy.

RESULTS:

Between July 30, 2012, and December 12, 2015, 375 patients were recruited from 54 centers and randomly assigned to receive prophylactic radiotherapy (n = 186) or no prophylactic radiotherapy (n = 189). Participants were well matched at baseline. No significant difference was seen in the incidence of CWM at 6 months between the prophylactic radiotherapy and no radiotherapy groups (no. [%]: 6 [3.2] v 10 [5.3], respectively; odds ratio, 0.60; 95% CI, 0.17 to 1.86; P = .44). Skin toxicity was the most common radiotherapy-related adverse event in the prophylactic radiotherapy group, with 96 patients (51.6%) receiving grade 1; 19 (10.2%), grade 2; and 1 (0.5%) grade 3 radiation dermatitis (Common Terminology Criteria for Adverse Events, version 4.0).

CONCLUSION:

There is no role for the routine use of prophylactic irradiation to chest wall procedure sites in patients with MPM.

• Authors: Neil Bayman, Wiebke Appel, Linda Ashcroft, David R Baldwin, Andrew Bates, Liz Darlison, John G Edwards, Veni Ezhil, David Gilligan, Matthew Hatton, Apurna Jegannathen, Talal Mansy, Michael D Peake, Laura Pemberton, Robert C Rintoul, Michael Snee, W David Ryder, Paul Taylor, Corinne Faivre-Finn
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 37 Issue 14 Pg. 1200-1208 (05 10 2019) ISSN: 1527-7755 [Electronic] United States
• PMID: 30920878 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Topics

• Aged
• Aged, 80 and over
• Female
• Humans
• Lung Neoplasms (pathology, radiotherapy)
• Male
• Mesothelioma (pathology, radiotherapy)
• Mesothelioma, Malignant
• Middle Aged
• Pleural Neoplasms (pathology, radiotherapy)
• Thoracic Neoplasms (prevention & control, radiotherapy, secondary)
• Thoracic Wall (pathology, radiation effects)